CytomX Therapeutics Inc [NASDAQ: CTMX] loss -1.56% on the last trading session, reaching $4.43 price per share at the time.
If compared to the average trading volume of 4.52M shares, CTMX reached a trading volume of 11065939 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about CytomX Therapeutics Inc [CTMX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTMX shares is $3.95 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTMX stock is a recommendation set at 2.57. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for CytomX Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 22, 2024. While these analysts kept the previous recommendation, BMO Capital Markets dropped their target price from $3 to $2.60. The new note on the price target was released on November 14, 2022, representing the official price target for CytomX Therapeutics Inc stock. Previously, the target price had yet another drop from $6 to $2, while Wedbush kept a Neutral rating on CTMX stock. On July 07, 2022, analysts decreased their price target for CTMX shares from 10 to 1.50.
The Average True Range (ATR) for CytomX Therapeutics Inc is set at 0.47, with the Price to Sales ratio for CTMX stock in the period of the last 12 months amounting to 2.98.
Trading performance analysis for CTMX stock
CytomX Therapeutics Inc [CTMX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 178.62. With this latest performance, CTMX shares gained by 115.05% in over the last four-week period, additionally plugging by 310.19% over the last 6 months – not to mention a rise of 168.48% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTMX stock in for the last two-week period is set at 75.85, with the RSI for the last a single of trading hit 77.71, and the three-weeks RSI is set at 73.91 for CytomX Therapeutics Inc [CTMX]. The present Moving Average for the last 50 days of trading for this stock 2.24, while it was recorded at 3.46 for the last single week of trading, and 1.64 for the last 200 days.
CytomX Therapeutics Inc [CTMX]: A deeper dive into fundamental analysis
CytomX Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.17 and a Current Ratio set at 1.17.
CytomX Therapeutics Inc [CTMX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CTMX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for CytomX Therapeutics Inc go to -0.90%.
An analysis of Institutional ownership at CytomX Therapeutics Inc [CTMX]
The top three institutional holders of CTMX stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in CTMX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in CTMX stock with ownership which is approximately 5.8386%.
